This segment focuses on the development and commercialization of innovative therapies for retinal diseases, including wet age-related macular degeneration (AMD), diabetic retinopathy, and retinal vein occlusion (RVO). EyePoint leverages its proprietary Durasert® technology for sustained drug delivery to the back of the eye, aiming to reduce the frequency of injections and improve patient outcomes. Research and development efforts are directed towards novel formulations and drug candidates that target key pathways involved in retinal disease progression. Clinical trials are conducted to evaluate the safety and efficacy of these therapies, with a focus on achieving regulatory approvals and market access. The segment aims to establish EyePoint as a leader in retinal disease treatment by providing differentiated products that address unmet medical needs and improve the quality of life for patients with vision-threatening conditions.

This segment is dedicated to developing and marketing treatments for ocular inflammation and uveitis, a chronic inflammatory condition affecting the eye. EyePoint's YUTIQ® product, an intravitreal implant for chronic non-infectious uveitis, exemplifies the company's commitment to providing long-lasting therapeutic solutions. Research and development activities focus on improving drug delivery methods and identifying new targets for inflammation control in the eye. Clinical trials are designed to demonstrate the safety and efficacy of these treatments, with the goal of expanding their use in various inflammatory eye conditions. The segment aims to offer effective and convenient treatment options that reduce the burden of frequent eye drops or injections, thereby improving patient compliance and visual outcomes. Strategic partnerships and collaborations are pursued to enhance the development and commercialization of these therapies.